Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

Zhang, Huimin; Qin, Chunhong; An, Changming; Zheng, Xian; Wen, Shuxin; Chen, Wenjie; Liu, Xiangguo; Lv, Zhenghua; Yang, Ping‐Chang; Xu, Wei; Gao, Wei; Wu, Yongyan

doi:10.1186/s12943-021-01431-6

Cited by 143 publications

(84 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We still need better modeling methods and tumor observation methods, and pay attention to the humanization of animal models in order to simulate more realistic tumor growth in humans ( Hu et al, 2016 ; De La Rochere et al, 2018 ; Ito et al, 2018 ; Tian et al, 2020 ). Secondly, in terms of inclusion, although CRISPR/Cas9-based gene-editing technology is stable, efficient, simple, and widely used, some problems remain, such as the off-target effect, targeted mutation, and immune response of human body to bacteria-derived Cas9 protein ( Zhang H. et al, 2021 ). One of the most promising applications of CRISPR/Cas9 in gene therapy is CAR T-cell therapy.…”

Section: Discussionmentioning

confidence: 99%

Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy

Yang

Suo

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Malignant tumors pose a serious threat to human health and have high fatality rates. Conventional clinical anti-tumor treatment is mainly based on traditional surgery, chemotherapy, radiotherapy, and interventional therapy, and even though these treatment methods are constantly updated, a satisfactory efficacy is yet to be obtained. Therefore, research on novel cancer treatments is being actively pursued. We review the classification of gene therapies of malignant tumors and their advantages, as well as the development of gene editing techniques. We further reveal the nano-drug delivery carrier effect in improving the efficiency of gene editing. Finally, we summarize the progress in recent years of gene editing techniques based on nano-drug delivery carriers in the treatment of various malignant tumors, and analyze the prospects of the technique and its restricting factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy

Yang

Suo

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…The application of the CRISPR-Cas9 as a gene-editing tool in different research fields has been widely studied, and several reviews on its fundamental principles, variations, and applications in cancer research have been published 13 - 17 . The pooled library screening approach, using CRISPR-Cas9 based gene-editing tool, has evolved as a powerful way to identify interesting gene mutations through phenotypic changes or viability screens.…”

Section: Varieties Of Crispr-cas9 Pooled Librariesmentioning

confidence: 99%

CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives

Zhang

et al. 2022

Theranostics

View full text Add to dashboard Cite

CRISPR-Cas9 is a Nobel Prize-winning robust gene-editing tool developed in the last decade. This technique enables a stable genetic engineering method with high precision on the genomes of all organisms. The latest advances in the technology include a genome library screening approach, which can detect survival-essential and drug resistance genes via gain or loss of function. The versatile machinery allows genomic screening for gene activation or inhibition, and targets non-coding sequences, such as promoters, miRNAs, and lncRNAs. In this review, we introduce the emerging high-throughput CRISPR-Cas9 library genome screening technology and its working principles to detect survival and drug resistance genes through positive and negative selection. The technology is compared with other existing approaches while focusing on the advantages of its variable applications in anti-cancer drug discovery, including functions and target identification, non-coding RNA information, actions of small molecules, and drug target discoveries. The combination of the CRISPR-Cas9 system with multi-omic platforms represents a dynamic field expected to advance anti-cancer drug discovery and precision medicine in the clinic.

show abstract

“…In the past few years, the development of a CRISPR–Cas9 system unveiled a world of new opportunities for the therapeutic targeting of not only coding but also noncoding genes [ 58 ]. The CRISPR/Cas9 system has emerged as an excellent option for miRNA therapeutic inhibition.…”

Section: Mirna-based Therapies In Nhlmentioning

confidence: 99%

miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin’s Lymphoma: Moving towards an RNA-Guided Precision Medicine

Fernandes

Marques

Teixeira

et al. 2021

Cancers

View full text Add to dashboard Cite

Increasing evidence has demonstrated the functional roles of miRNAs and lncRNAs in lymphoma onset and progression, either by acting as tumor-promoting ncRNAs or as tumor suppressors, emphasizing their appeal as lymphoma therapeutics. In fact, their intrinsic ability to modulate multiple dysregulated genes and/or signaling pathways makes them an attractive therapeutic approach for a multifactorial pathology like lymphoma. Currently, the clinical application of miRNA- and lncRNA-based therapies still faces obstacles regarding effective delivery systems, off-target effects, and safety, which can be minimized with the appropriate chemical modifications and the development of tumor site-specific delivery approaches. Moreover, miRNA- and lncRNA-based therapeutics are being studied not only as monotherapies but also as complements of standard treatment regimens to provide a synergic effect, improving the overall treatment efficacy and reducing the therapeutic resistance. In this review, we summarize the fundamentals of miRNA- and lncRNA-based therapeutics by discussing the different types of delivery systems, with a focus on those that have been investigated in lymphoma in vitro and in vivo. Moreover, we described the ongoing clinical trials of novel miRNA- and lncRNA-based therapeutics in lymphoma.

show abstract

Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

Cited by 143 publications

References 212 publications

Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy

Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy

CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives

miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin’s Lymphoma: Moving towards an RNA-Guided Precision Medicine

Contact Info

Product

Resources

About